| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-14-3222 |
| P698 | PubMed publication ID | 26169969 |
| P50 | author | Camino Menéndez | Q83830518 |
| Josep Tabernero Caturla | Q37387600 | ||
| Manuel Hidalgo | Q37392552 | ||
| Pedro P López-Casas | Q51826156 | ||
| Monica Musteanu | Q56037068 | ||
| P2093 | author name string | Daniel D Von Hoff | |
| Fernando Lopez-Rios | |||
| Alfredo Romano | |||
| Carlos Plaza | |||
| Carla Heise | |||
| Xinyu Wei | |||
| Peter Illei | |||
| Daniel Pierce | |||
| Carrie B Brachmann | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 4811-4818 | |
| P577 | publication date | 2015-07-13 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial | |
| P478 | volume | 21 |
| Q52603515 | A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. |
| Q47110205 | A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients |
| Q59137239 | ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy |
| Q37742975 | Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. |
| Q64233995 | Advances in pancreatic cancer biomarkers |
| Q92140598 | Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review |
| Q33884827 | Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel |
| Q52739894 | Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? |
| Q48304217 | Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy? |
| Q47782363 | Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy. |
| Q39015961 | Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings |
| Q60609732 | Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. |
| Q60950025 | Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches |
| Q38670577 | Current and future biomarkers for pancreatic adenocarcinoma |
| Q33803923 | Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression |
| Q48219198 | Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? |
| Q37542844 | Drug metabolism and pancreatic cancer |
| Q39158427 | Emerging antibodies for the treatment of pancreatic cancer. |
| Q28075540 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer |
| Q48873577 | Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer |
| Q38689014 | Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. |
| Q90251494 | Harnessing albumin as a carrier for cancer therapies |
| Q49325052 | High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer |
| Q48232396 | How can next-generation diagnostics aid pancreatic adenocarcinoma treatment? |
| Q52725074 | How does the tumor microenvironment play a role in hepatobiliary tumors? |
| Q50191970 | Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials |
| Q89867988 | Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine |
| Q36578825 | Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization |
| Q37264732 | Metastatic progression is associated with dynamic changes in the local microenvironment |
| Q36843773 | Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. |
| Q40914660 | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial |
| Q41608480 | Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions |
| Q28077206 | Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma |
| Q38658509 | Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. |
| Q26748822 | Neoadjuvant nab-paclitaxel in the treatment of breast cancer |
| Q38900432 | Optimizing initial chemotherapy for metastatic pancreatic cancer |
| Q47135556 | Pancreatic Cancer Chemoresistance to Gemcitabine |
| Q39453559 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment |
| Q26770931 | Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis |
| Q92686120 | Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors |
| Q50072347 | Recent advances in the management of pancreatic adenocarcinoma |
| Q64269083 | Role of the tumor microenvironment in pancreatic cancer |
| Q90615581 | SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer |
| Q37191979 | SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy |
| Q48158172 | SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. |
| Q36917864 | SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts |
| Q38806041 | Safety of palliative chemotherapy in advanced pancreatic cancer |
| Q94461853 | Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma |
| Q38685933 | Stromal SPOCK1 supports invasive pancreatic cancer growth. |
| Q39577399 | Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer |
| Q57159994 | The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship |
| Q61809694 | The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection |
| Q39366753 | The pancreatic cancer microenvironment: A true double agent. |
| Q60609561 | Therapeutic developments in pancreatic cancer: current and future perspectives |
| Q90655994 | Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis |
| Q38742506 | Tubulin inhibitors in non-small cell lung cancer: looking back and forward |
| Q37254508 | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
| Q58561906 | [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma] |
Search more.